Edge Wealth Management LLC reduced its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 69.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 31,309 shares of the biopharmaceutical company’s stock after selling 70,453 shares during the quarter. Edge Wealth Management LLC’s holdings in Gilead Sciences were worth $1,958,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Sumitomo Mitsui Financial Group Inc. bought a new position in Gilead Sciences during the third quarter worth about $100,000. Reilly Financial Advisors LLC increased its position in Gilead Sciences by 98.3% during the third quarter. Reilly Financial Advisors LLC now owns 1,420 shares of the biopharmaceutical company’s stock worth $110,000 after acquiring an additional 704 shares during the period. North Star Investment Management Corp. increased its position in Gilead Sciences by 11.5% during the fourth quarter. North Star Investment Management Corp. now owns 2,199 shares of the biopharmaceutical company’s stock worth $138,000 after acquiring an additional 226 shares during the period. TRUE Private Wealth Advisors bought a new position in Gilead Sciences during the third quarter worth about $174,000. Finally, Vectors Research Management LLC bought a new position in Gilead Sciences during the third quarter worth about $178,000. 78.01% of the stock is currently owned by hedge funds and other institutional investors.
NASDAQ GILD traded up $0.08 during trading hours on Friday, reaching $68.12. The company’s stock had a trading volume of 432,232 shares, compared to its average volume of 8,381,735. The firm has a market cap of $87.89 billion, a PE ratio of 7.96, a price-to-earnings-growth ratio of -2.35 and a beta of 1.06. Gilead Sciences, Inc. has a 52 week low of $60.32 and a 52 week high of $89.54. The company has a debt-to-equity ratio of 1.09, a current ratio of 3.45 and a quick ratio of 3.37.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, October 25th. The biopharmaceutical company reported $1.84 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.63 by $0.21. Gilead Sciences had a net margin of 7.12% and a return on equity of 39.32%. The business had revenue of $5.60 billion during the quarter, compared to analyst estimates of $5.44 billion. During the same quarter last year, the business earned $2.27 EPS. As a group, research analysts anticipate that Gilead Sciences, Inc. will post 6.44 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which was paid on Friday, December 28th. Shareholders of record on Friday, December 14th were issued a dividend of $0.57 per share. The ex-dividend date was Thursday, December 13th. This represents a $2.28 annualized dividend and a yield of 3.35%. Gilead Sciences’s payout ratio is 26.64%.
In other Gilead Sciences news, Director John C. Martin sold 50,000 shares of the firm’s stock in a transaction that occurred on Monday, December 3rd. The shares were sold at an average price of $71.20, for a total transaction of $3,560,000.00. Following the completion of the transaction, the director now owns 2,877,762 shares in the company, valued at approximately $204,896,654.40. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 1.16% of the stock is currently owned by company insiders.
A number of equities research analysts have issued reports on the stock. Oppenheimer upgraded shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $85.00 price objective on the stock in a research note on Thursday, January 3rd. BidaskClub upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating in a research note on Thursday, October 11th. Zacks Investment Research downgraded shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Monday, December 31st. CIBC upgraded shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $85.00 price objective on the stock in a research note on Thursday, January 3rd. Finally, ValuEngine upgraded shares of Gilead Sciences from a “sell” rating to a “hold” rating in a research note on Friday, September 28th. Ten research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company. Gilead Sciences currently has a consensus rating of “Buy” and a consensus price target of $88.39.
ILLEGAL ACTIVITY WARNING: “Edge Wealth Management LLC Sells 70,453 Shares of Gilead Sciences, Inc. (GILD)” was posted by Stock Observer and is the property of of Stock Observer. If you are reading this article on another domain, it was illegally copied and republished in violation of U.S. & international copyright laws. The legal version of this article can be accessed at https://www.thestockobserver.com/2019/01/11/edge-wealth-management-llc-sells-70453-shares-of-gilead-sciences-inc-gild.html.
Gilead Sciences Profile
Gilead Sciences, Inc discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.